This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cho, D. Articles by Atkins, M. B. Search for Related Content PubMed PubMed Citation Articles by Cho, D. Articles by Atkins, M. B.

The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer

Authors' Affiliations: ¹ Beth Israel Deaconess Medical Center; ² Brigham and Women's Hospital; ³ Dana-Farber Cancer Institute; and ⁴ Renal Cancer Program, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts

Requests for reprints: Michael B. Atkins, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. E-mail: matkins{at}bidmc.harvard.edu.

Inhibitors of the mammalian target of rapamycin (mTOR) have shown promising efficacy in early-stage trials in patients with advanced renal cell carcinoma (RCC). Most RCCs have been shown to possess biallelic alterations in the von Hippel-Lindau (VHL) gene, resulting in accumulation of hypoxia-inducible factors 1 and 2, as well as their downstream targets including vascular endothelial growth factor (VEGF). The observed clinical efficacy of mTOR inhibitors in patients with RCC may be mediated in part by the dependence of efficient hypoxia-inducible factor translation on the mTOR pathway. mTOR inhibitors have entered more advanced phase clinical trials either as single agents or in combination with other targeted agents or IFN, which might ultimately result in regulatory approval of one or more agents. Given the likely nonoverlapping mechanism of action of mTOR inhibitors and VEGF pathway–targeted agents, mTOR inhibitors may prove useful if administered in combination or after resistance to VEGF inhibitors. With an increasing number of active agents for treatment of patients with RCC, efforts must continue to develop patient selection models based on predictive biomarkers to direct therapy to appropriate patients.

This article has been cited by other articles:

				T. E. Hutson, R. A. Figlin, J. G. Kuhn, and R. J. Motzer Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies Oncologist, October 1, 2008; 13(10): 1084 - 1096. [Abstract] [Full Text] [PDF]

				M. J. Ratain and E. E. Cohen The Value Meal: How to Save $1,700 Per Month or More on Lapatinib J. Clin. Oncol., August 10, 2007; 25(23): 3397 - 3398. [Full Text] [PDF]